Number of pages: 100 | Report Format: PDF | Published date: November 02, 2022
Historical Years – 2020 | Base Year – 2021 | Forecasted Years – 2022-2030
The global anti-inflammatory drugs market was pegged at US$ 95.13 billion in 2021 and is expected to witness a CAGR of 9.3% during the forecast period from 2022 to 2030.
Inflammation is an intrinsic immunological process in humans that is largely engaged to remove dead cells and eradicate the source of harm. Anti-inflammatory medications help to alleviate both acute and chronic pain, such as that caused by injuries, inflammatory response, autoimmune conditions aging, and so on. When compared to traditional drugs, novel anti-inflammatory drugs provide faster and safer relief. They can reduce pain and swelling by decreasing the amounts of prostaglandins and the substances that cause inflammation. Anti-inflammatory medications often target anti-inflammatory mediators or enzymes.
The global anti-inflammatory drugs market is a large industry and is expected to grow at a rapid pace in the projected period. This growth can be attributed to the growing prevalence of chronic pain, autoimmune, and respiratory conditions with an exponential rise in the aged population. Additionally, a strong pipeline, increasing adoption of anti-inflammatory drugs, and growing awareness of anti-inflammatory therapeutics contribute to market growth. Furthermore, increasing R&D activities, the growing usage of nanotechnologies and other novel drug delivery systems, and the continuous launch of new products also boost the market growth for anti-inflammatory drugs. Additionally, the growing adoption of non-steroidal anti-inflammatory drugs and rising surgical and/or therapeutic procedures due to increasing road accidents further propel the growth of the anti-inflammatory market globally. However, drug failures in clinical trials and the side effects of these drugs especially due to non-steroidal anti-inflammatory drugs (NSAIDs) such as kidney failure, allergic reactions, dizziness, etc. can be major hurdles to the optimal growth of this market.
The global anti-inflammatory drugs market has been analyzed from five perspectives: drug class, indication, route of administration, distribution channel, and region.
Anti-Inflammatory Drugs Market by Drug Class
The global anti-inflammatory drugs market has been segmented based on drug class into anti-inflammatory biologics, corticosteroids, immune selective anti-inflammatory derivatives (ImSAIDs), and nonsteroidal anti-inflammatory drugs (NSAIDs). Anti-inflammatory biologics dominates the market with the largest revenue share. This growth can be attributed to the high utilization of these drugs and higher drug cost than conventional medications. Biologics are being increasingly used in everyday practice to dramatically slow disease progression by lowering pain and swelling, joint damage, and increasing health-related quality of life in patients with arthritis, multiple sclerosis, psoriasis, and GI inflammation. The key drivers of the segment growth include new product releases, increased acceptance of monoclonal antibodies, and the introduction of biosimilars.
Simultaneously, nonsteroidal anti-inflammatory drugs (NSAIDs) hold the second largest share in the market. High uptake of NSAIDs is attributed to consistently high demand for over-the-counter (OTC) anti-inflammatory therapeutics, and the rising prevalence of inflammatory disorders such as arthritis. Furthermore, high utilization of NSAIDs as the first line of treatment for inflammation and pain, also supports the position of this segment. However, the side effects associated with NSAIDs and growing availability of substitution from safer treatments may restrain the market growth through the forecast period.
Anti-Inflammatory Drugs Market by Indication
Based on the indication, the global anti-inflammatory drugs market has been segmented into Inflammatory bowel disease (IBD), arthritis, multiple sclerosis, respiratory diseases, and others. Arthritis dominates the segment with the largest revenue share and is attributed to the high prevalence of arthritis due to poor lifestyles and unhealthy diets. Additionally, the increasing geriatric population and the corresponding prescription of NSAIDs, and the large availability of many approved drugs for age-related chronic pain support the market growth.
Anti-Inflammatory Drugs Market by Route of Administration
Based on the route of administration, the global anti-inflammatory drugs market has been classified into oral, injection, and others (topical and inhalation). Injection dominates the segment with the largest revenue share, attributed to high utilization of injectable NSAIDs and biologics. Oral administration is the second largest shareholder in this segment due to the high utilization of generic drugs for various inflammatory diseases.
Anti-Inflammatory Drugs Market by Distribution Channel
According to distribution channels, the global anti-inflammatory drugs market is classified into hospital pharmacies, online pharmacies, and retail pharmacies. The hospital pharmacies segment dominates the global anti-inflammatory drugs market due to high patient footfall and convenient access in emergency cases. Due to the growing incidences of various inflammatory disorders such as arthritis, multiple sclerosis, etc., and increased patient demand for OTC drugs, retail pharmacies have the second-largest market share.
Anti-Inflammatory Drugs Market by Region
The global anti-inflammatory drugs market has been segmented based on regions into North America, Europe, Asia Pacific, and the Rest of the World. North America leads the global anti-inflammatory drugs market with the largest revenue share. It is also expected to maintain its dominance in the forecast period. This market's expansion may be ascribed to several factors, including the high incidences of inflammatory disorders, the large base of geriatric population, and the widespread presence of sophisticated healthcare infrastructure. North America market is further growing due to rapid expansion of R&D activities, technological progress, and high healthcare spending. The market is also expected to rise due to the approval of innovative products and drugs and a large base of market players. Due to its developed healthcare infrastructure and high healthcare spending, Europe is the second largest stakeholder.
A growing geriatric population base, the rapidly evolving healthcare sector, and the growing adoption of innovative technologies are driving the growth of the Asia Pacific market. Expanding the anti-inflammatory drugs market in Asia is further fueled by expanding medical tourism and increased healthcare expenditure for improved medical facilities.
The prominent players operating in the global anti-inflammatory drugs market are:
The global anti-inflammatory drugs market is expected to be US$ 211.79 billion in 2030.
The factors restraining the optimal growth of the global anti-inflammatory drugs market are drug failures in clinical trials and the side effects of NSAIDs.
The global anti-inflammatory drugs market is expected to grow at a CAGR of 9.3% during the forecast period from 2022 to 2030.
The global anti-inflammatory drugs market was estimated to be US$ 95.13 billion in 2021.
The rise in the prevalence of arthritis, multiple sclerosis, inflammatory bowel disease, etc.; growth in the geriatric population; advancement in technologies; and rapid growth in R&D activities are some factors driving the market growth.
*Insights on financial performance is subject to availability of information in public domain